. Summary Information
|
|
|
Country |
|
|
Company Name |
UNIDRUG
INNOVATIVE PHARMA TECHNOLOGIES LIMITED |
Principal Name 1 |
Mr. Jainesh Jain |
|
Status |
Satisfactory |
Principal Name 2 |
Mrs. Varsha Jain |
|
|
|
Registration # |
10-003875 |
|
Street Address |
Plot No.84,
Sector – E, Sanwer Road, Indore - 452015, Madhya Pradesh |
||
|
Established Date |
13.03.1987 |
SIC Code |
-- |
|
Telephone# |
91-731-2720402 / 4047364 / 4047663 / 2533324 |
Business Style 1 |
Manufacturer |
|
Fax # |
91-731-2533576 |
Business Style 2 |
-- |
|
Homepage |
Product Name 1 |
Tnidazole |
|
|
# of employees |
Not Available |
Product Name 2 |
Ornidazole |
|
Paid up capital |
Rs.19,660,000/- |
Product Name 3 |
Allopurinol |
|
Shareholders |
Directors or
relatives of Directors – 100.00% |
Banking |
Punjab National Bank |
|
Public Limited Corp. |
No |
Business Period |
25 Years |
|
IPO |
No |
International Ins. |
- |
|
Public |
No |
Rating |
Ba (45) |
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
-- |
-- |
-- |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
92,342,000 |
Current Liabilities |
43,708,000 |
|
Inventories |
31,355,000 |
Long-term Liabilities |
64,600,000 |
|
Fixed Assets |
33,082,000 |
Other Liabilities |
70,24,000 |
|
Deferred Assets |
0,000 |
Total Liabilities |
115,332,000 |
|
Invest& other Assets |
2,200,000 |
Retained Earnings |
23,987,000 |
|
|
|
Net Worth |
43,647,000 |
|
Total Assets |
158,979,000 |
Total Liab. & Equity |
158,979,000 |
|
Total Assets (Previous Year) |
149,909,000 |
|
|
|
P/L Statement as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Sales |
234,749,000 |
Net Profit |
1,836,000 |
|
Sales(Previous yr) |
237.372,000 |
Net Profit(Prev.yr) |
2,567,000 |
|
Report Date : |
13.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
UNIDRUG INNOVATIVE PHARMA TECHNOLOGIES LIMITED (w.e.f.17.09.1996) |
|
|
|
|
Formerly Known
As : |
UNI DRUG LIMITED |
|
|
|
|
Registered
Office : |
Plot No.84, Sector – E, Sanwer Road, Indore - 452015, Madhya Pradesh |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
13.03.1987 |
|
|
|
|
Com. Reg. No.: |
10-003875 |
|
|
|
|
Capital Investment
/ Paid-up Capital : |
Rs.19.660 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U85120MP1987PLC003875 |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of bulk drugs like Tnidazole, Ornidazole, Allopurinol,
Chlarzoxazone, Disulfiram. |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (45) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 170000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having satisfactory track. Trade
relations are reported as fair. Business is active. Payments are reported to
be usually correct and as per commitments. The company can be considered normal for business at usual trade terms
and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office : |
Plot No.84, Sector – E, Sanwer Road, Indore - 452015, Madhya Pradesh,
India |
|
Tel. No.: |
91-731-2720402 / 4047364 / 4047663 / 2533324 |
|
Fax No.: |
91-731-2533576 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Administrative Office : |
115, Bansi Trade Centre, 581/5, M G Road, Indore, Madhya Pradesh – 452015, India |
|
Tel. No.: |
91-731-2533324 / 2533576 |
DIRECTORS
As on 30.09.2011
|
Name : |
Mr. Jainesh Jain |
|||||||||||||||||||||||||||
|
Designation : |
Managing Director |
|||||||||||||||||||||||||||
|
Address : |
13/2 – New Palasia, Indor – 452001, Madhya Pradesh, India |
|||||||||||||||||||||||||||
|
Date of Birth/Age : |
12.11.1972 |
|||||||||||||||||||||||||||
|
Date of Appointment : |
20.08.1995 |
|||||||||||||||||||||||||||
|
DIN No.: |
02355170 |
|||||||||||||||||||||||||||
|
Other
Directorship:
|
||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Name : |
Mrs. Varsha Jain |
|||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||
|
Address : |
13/2 – New Palasia, Indor – 452001, Madhya Pradesh, India |
|||||||||||||||||||||||||||
|
Date of Birth/Age : |
24.06.1977 |
|||||||||||||||||||||||||||
|
Date of Appointment : |
05.10.1995 |
|||||||||||||||||||||||||||
|
DIN No.: |
00255907 |
|||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Name : |
Mrs. Kanaklata Jain |
|||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||
|
Address : |
13/2 – New Palasia, Indor – 452001, Madhya Pradesh, India |
|||||||||||||||||||||||||||
|
Date of Birth/Age : |
20.10.1951 |
|||||||||||||||||||||||||||
|
Date of Appointment : |
29.05.1968 |
|||||||||||||||||||||||||||
|
DIN No.: |
00234125 |
|||||||||||||||||||||||||||
|
Other
Directorship:
|
||||||||||||||||||||||||||||
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 30.09.2011
|
Names of Shareholders |
|
No. of Shares |
|
Jainesh Jain |
|
588200 |
|
Kanaklata Jain |
|
7728400 |
|
T C Jain |
|
7722000 |
|
Bharat Jain |
|
552200 |
|
Varsha Jain |
|
2502200 |
|
Rachana Jain |
|
536000 |
|
Abhay Kumar Jain |
|
31000 |
|
|
|
|
|
Total |
|
19660000 |
Equity Share Break up (Percentage of Total Equity)
As on 30.09.2011
|
Category |
Percentage |
|
Directors or relatives of Directors |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of bulk drugs like Tnidazole, Ornidazole, Allopurinol,
Chlarzoxazone, Disulfiram. |
|
|
|
|
|
|
Products : |
ITC No |
Product Description |
|
|
2933.29 |
Ornidazole |
|
|
2933.29 |
Tinidazole |
|
|
-- |
Other Basic Drugs |
PRODUCTION STATUS (As on 31.03.2011)
|
Particulars |
Unit |
Licensed
Capacity |
Installed
Capacity |
|
Basic Drugs and Chemicals (on single shift basis) |
MT |
300 |
300 |
|
Particulars |
Unit |
Actual Production |
|
Tinidazole |
Kg |
84293 |
|
Ornidazole |
Kg |
172911 |
|
Chlorzoxazone |
Kg |
685 |
|
Alprazolam |
Kg |
193.5 |
|
Allopurinol |
Kg |
4800 |
|
Disulfiram |
Kg |
7025 |
|
Guaifenesin |
Kg |
6600 |
GENERAL INFORMATION
|
Customers : |
·
Akums Drugs and Pharmaceuticals ·
Alkem Laboratories Limited ·
Alpa Labs Limited ·
Ankur Drugs and Pharma Limited ·
Aristo Pharmaceuticals Limited ·
Bafna Pharmaceuticals Limited ·
Cadila Pharmaceuticals Limited ·
Cipla Limited ·
Deys Medical Stores (Mfg) Limited ·
Emcure Pharma Limited ·
FDC Limited ·
Intas Pharma Limited ·
IPCA Labs Limited ·
Khandelwal Labs Limited ·
Lupin Limited ·
Macleods Pharmaceuticals Limited ·
Makers Laboratories Limited ·
Mankind Pharma Limited ·
Medley Pharmaceuticals Limited ·
Ozone Pharmaceuticals Limited ·
Parenteral Drugs Limited ·
Plethico Pharmaceuticals Limited ·
The Madras Pharmaceuticals ·
Torrent Pharma Limited ·
Zydus Cadila Limited |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
No. of Employees : |
Not Available |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Bankers : |
·
Punjab National Bank, Manoramaganj Branch, Palasia
Square, Indore – 452001, Madhya Pradesh, India ·
ICICI Bank |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Facilities : |
(Rs. in Millions)
|
||||||||||||||||||||||||||||||
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
S N Gadiya and Company Chartered Accountants |
|
Address : |
241 Apollo Towers, 2 M G Raod, Indore – 452003, Madhya Pradesh, India |
|
PAN.: |
ABQPG0113K |
CAPITAL STRUCTURE
As on 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
50000000 |
Equity Shares |
Rs.1/- each |
Rs.50.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
19660000 |
Equity Shares |
Rs.1/- each |
Rs.19.660
Millions |
|
|
|
|
|
Note:
Of the above 9830000 equity shares of Re. 1/- each fully paid up have
been issued as bonus shares by capitalisation of reserves)
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
19.660 |
19.660 |
19.660 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
23.987 |
22.151 |
19.660 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
43.647 |
41.811 |
39.320 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
50.375 |
51.415 |
54.059 |
|
|
2] Unsecured Loans |
14.225 |
11.119 |
10.091 |
|
|
TOTAL BORROWING |
64.600 |
62.534 |
64.150 |
|
|
DEFERRED TAX LIABILITIES |
6.427 |
6.644 |
6.046 |
|
|
|
|
|
|
|
|
TOTAL |
114.674 |
110.989 |
109.516 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
33.082 |
34.921 |
33.342 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
2.200 |
2.200 |
2.200 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
31.355
|
34.012 |
29.576 |
|
|
Sundry Debtors |
69.233
|
52.057 |
50.346 |
|
|
Cash & Bank Balances |
7.426
|
5.978 |
3.272 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
15.683
|
20.741 |
14.677 |
|
Total
Current Assets |
123.697
|
112.788 |
97.871 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
39.630
|
38.144 |
23.026 |
|
|
Other Current Liabilities |
4.078
|
0.219 |
0.440 |
|
|
Provisions |
0.597
|
0.557 |
0.431 |
|
Total
Current Liabilities |
44.305
|
38.920 |
23.897 |
|
|
Net Current Assets |
79.392
|
73.868 |
73.974 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
114.674 |
110.989 |
109.516 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
234.749 |
237.372 |
239.235 |
|
|
|
Other Income |
1.165 |
2.784 |
2.236 |
|
|
|
TOTAL (A) |
235.914 |
240.156 |
241.471 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Operating Expenses |
218.063 |
219.874 |
220.270 |
|
|
|
Administrative Expenses |
3.408 |
1.744 |
2.725 |
|
|
|
Selling Expenses |
3.356 |
2.160 |
1.685 |
|
|
|
Directors Remuneration |
1.200 |
1.200 |
0.900 |
|
|
|
Increase/ (Decrease) in Finished Goods |
(2.557) |
1.472 |
0.508 |
|
|
|
TOTAL (B) |
223.470 |
226.450 |
226.088 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
12.444 |
13.706 |
15.383 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
7.801 |
7.533 |
8.752 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
4.643 |
6.173 |
6.631 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
2.656 |
2.429 |
2.303 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
1.987 |
3.744 |
4.328 |
|
|
|
|
|
|
|
|
|
Less |
TAX (I) |
0.151 |
1.177 |
1.490 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-I) (J) |
1.836 |
2.567 |
2.838 |
|
|
|
|
|
|
|
|
|
|
PRIOR PERIOD
EXPENSES |
0.000 |
0.000 |
(0.003) |
|
|
|
|
|
|
|
|
|
|
BALANCE |
0.000 |
(0.076) |
0.000 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
10.431 |
7.940 |
14.935 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to Reserve |
0.000 |
0.000 |
(9.830) |
|
|
BALANCE CARRIED
TO THE B/S |
12.267 |
10.431 |
7.940 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Value of goods imported |
82.484 |
77.244 |
44.595 |
|
|
TOTAL IMPORTS |
82.484 |
77.244 |
44.595 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
0.09 |
0.13 |
0.15 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
PAT / Total Income |
(%) |
0.78
|
1.07 |
1.18 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
0.85
|
1.58 |
1.81 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
1.61
|
3.32 |
4.42 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.05
|
0.09 |
0.11 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
1.02
|
0.93 |
0.61 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.79
|
2.90 |
4.10 |
LOCAL AGENCY FURTHER INFORMATION
|
Check List by
Info Agents |
Available in
Report (Yes / No) |
|
1) Year of Establishment |
Yes |
|
2) Locality of the firm |
Yes |
|
3) Constitutions of the firm |
Yes |
|
4) Premises details |
No |
|
5) Type of Business |
Yes |
|
6) Line of Business |
Yes |
|
7) Promoter’s background |
Yes |
|
8) No. of employees |
No |
|
9) Name of person contacted |
No |
|
10) Designation of contact person |
No |
|
11) Turnover of firm for last three years |
Yes |
|
12) Profitability for last three years |
Yes |
|
13) Reasons for variation <> 20% |
-- |
|
14) Estimation for coming financial year |
No |
|
15) Capital in the business |
Yes |
|
16) Details of sister concerns |
No |
|
17) Major suppliers |
No |
|
18) Major customers |
Yes |
|
19) Payments terms |
No |
|
20) Export / Import details (if applicable) |
No |
|
21) Market information |
-- |
|
22) Litigations that the firm / promoter involved in |
-- |
|
23) Banking Details |
Yes |
|
24) Banking facility details |
Yes |
|
25) Conduct of the banking account |
-- |
|
26) Buyer visit details |
-- |
|
27) Financials, if provided |
Yes |
|
28) Incorporation details, if applicable |
Yes |
|
29) Last accounts filed at ROC |
Yes |
|
30) Major Shareholders, if available |
Yes |
BANKERS CHARGES
REPORT AS PER REGISTRY
|
Corporate identity number of the company |
U85120MP1987PLC003875 |
|
Name of the company |
UNIDRUG
INNOVATIVE PHARMA TECHNOLOGIES LIMITED |
|
Address of the registered office or of the
principal place of business in |
Plot No.84, Sector
– E, Sanwer Road, Indore, Madhya Pradesh, India Email: unidrug@gmail.com |
|
This form is for |
Creation of charge |
|
Type of charge |
Book debts Movable property
(not being pledge) |
|
Particular of charge holder |
Punjab National
Bank, Manoramaganj Branch, Palasia Square, Indore – 452001, Madhya Pradesh,
India Email: bo0699@pnb.co.in |
|
Nature of instrument creating charge |
1. Master
Agreement for documentary credit 2. Deed of
hypothecation to secure LC on DA basis |
|
Date of instrument Creating the charge |
16.12.2011 |
|
Amount secured by the charge |
Rs.4.000
Millions |
|
Brief of the principal terms an conditions
and extent and operation of the charge |
Rate of Interest Nil Terms of Repayment as per documentary credit established Margin 10% of the amount of documentary credit Extent and Operation of the charge Rs.4.000 Millions |
|
Short particulars of the property or
asset(s) charged (including complete address and location of the property) |
1. Goods /
assets represented by documents drawn/covered under Letter of credit issued
under the above said limit. 2(a) various raw
material 2(b) stock in
process and semi finished goods 2(c) Finished
Goods 2(d) Packaging
Materials |
FIXED ASSETS
·
Plant and Machinery
·
Pollution Control equipments
·
Building
·
Tubwell
·
Furniture and Fixtures
·
Office Equipment
·
Electric Installation
·
Land
·
Land Development
·
Computers Software and Peripherals
·
Vehicle
AS PER WEBSITE
DETAILS:
PROFILE:
A relatively Young company that is making its presence felt and making
rapid progress nationally and internationally.
Involved in the manufacturing of active pharmaceutical ingredients
subject is one of its kind of the very few companies which have been able to
carve a niche in the pharmaceutical industry given the present scenario where
it requires a right blend of intellectual strength, core competencies and a
precise foresight for the future.
All the products are being manufactured as per WHO GMP norms by the team
of more than 150 experienced and trained personnel and technicians to provide
high quality products to the valued customers, Specially trained personnel /
technicians and smoothly running sales network proves that they take their
obligations to their products and their discerning customers more serious than
ever.
Subject has come a long way since its inception in the year 1997 to be
recognized as a strong player in the field of pharmaceuticals, as result of its
combined strength in research manufacture and marketing.
During it's short history the company has emerged as a Quality Leader in
Antiprotozole segment of bulk drug industry of the country.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.56.05 |
|
|
1 |
Rs.86.69 |
|
Euro |
1 |
Rs.69.98 |
INFORMATION DETAILS
|
Report Prepared
by : |
KVT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
4 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
45 |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.